Efficacy of filgrastim to prevent neutropenia in patients with lung cancer treated with cyclophosphamide, doxorubicin and etoposide chemotherapy regimens.

Trial Profile

Efficacy of filgrastim to prevent neutropenia in patients with lung cancer treated with cyclophosphamide, doxorubicin and etoposide chemotherapy regimens.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2014

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 10 Jun 2014 New trial record
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 30 May 2014 Primary endpoint 'Infection-rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top